$ENTB-Zander Therapeutics – Big Pharma Like BMS Are Battling To Buy Undervalued Stem Cell Companies
$ENTB-Zander Therapeutics – Big Pharma Like BMS Are Battling To Buy Undervalued Stem Cell Companies
Sep. 27, 2017 12:00 PM ET|Includes: Entest BioMedical Inc. (ENTB) , RGBP
Summary
Big Pharma Paying $$$$ Top Dollar $$$$
Small Undervalued Stem Cells Acquired
NR2F6 Killing Cancer Genes/Cells-Activating Immune System
Treating Cancer, Auto-Immune-Lupus
Rare Blood Diseases & Bone Marrow Suppresion FDA Human Trials
$ENTB-Zander Therapeutics – Big Pharma Like BMS Are Battling to Buy Undervalued Stem Cell Companies
Entest BioMedical’s subsidiary is a “Cutting Edge-Undervalued” small stem cell focusing on new veterinary drugs and treatments
Receently Bristol Myers Squibb ( BMS ) acquired IMF Therapeutics for $2,300,000 - $2.3 Billion IMF is believed to only being a mere 6 months ahead of Regen
Summary
Zander Lincensed to use NR2F6*
NR2F6 Cancer Killing Potential
Utilizing Individuals Immune System**
Zander Therapeutics is making major discoveries and progress in creating new drugs for the veterinary industry.
ZT 100 is a NR2F6 inhibitor for Feline Leukemia
ZT 240 is a NR2F6 inhibitor for Canine Cancer
ZT 369 is a NR2F6 stimulator for (EIPH) exercise induced pulmonary hemorrhage (Equine)
ZT 430 is a stimulator for arthritis and auto immunity (Feline & Canine)
Licensed by Regen BioPharma ( OTCQB:RGBP )* www.regenbiopharmainc.com
RGBP Utilizing Immune Systems**
Zander Blood & Immune Systems
Zander is a subsidiary of Entest BioMedical
Entest is a subsidiary of Regen BioPharma
Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs with Novel NR2F6 Activators
Harry Lander - President and Chief Scientific Officer
“Thus far, we have met each & every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies, in the near future.”
Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics - Small molecule biotech companies fetching trophy values from large Pharma.
Another recent news item that could put ENTB or Zander on the map in the Veterinary World is the announcement of the Former Petco CEO joining the company.
ENTB Announces Brian Devine, Former Chairman of PETCO, to Head its Business Advisory Board
This could one day lead to a Presence with PETCO or Other Veterinary/Pet Businesses.
ENTB has also recently Retired All Their DEBT
We believe $ENTB although inexpensive as stocks come, is an excellent Long Play Small/Micro Cap that has the potential for Short Term Gains/Profits in the right climate and situations. They recently Retired All Debt.
It does need more visibility, which we are creating. More volume, positive volume, buying volume will allow for growth and an increase in share price.
Eventually this company will be noticed as a force in the veterinary medicine world. Will you be too late?
Take a close look at this little (DITR) Diamond in the Rough, the future could lead to agreements with Big Box Pet Stores (PETCO), and Vets all over the world, etc. For more information concerning $ENTB contact us and/or visit:
Yahoo Finance - Business Finance, Stock Market, Quotes, News or www.otcmarkets.com
Robert E. Kreh (Rob) - Principal
Small Cap Solutions, LLC
robkreh@smallcapsolutions.com
robkreh@gmail.com
( ENTB - RGBP ) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Entest Biomedical, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Entest Biomedical, Inc.(Zander Therapeutics) & Regen BioPharma, Inc. Additional inquiries are available by email torobkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile( S ) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.
Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or atyahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker( S )/Broker Dealer( S ) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
